ResMed Inc. (RMD-N)

They operate purely domestically, so are safe from tariffs. They report a solid quarter Wednesday and got exempted from tariffs. It could have more room to run.

His reservations about their GLP-1 business were misplaced, and the company is doing quite well.

Gagdets like Goggle Watch have shown people how poorly they sleep. Resmed makes sleep apnea machines, which sees big, growing demand, and they hold 90% of the market.

Shares have been knocked down. Good management.

18 million Americans have sleep apnea with many others undiagnosed. They have 2.5 billion nights of medical sleep data. They take cases out of hospitals and into homes. Based in Australia and the U.S. Shares have been been steadily rising. (1.3% dividend yield, Analysts' price target $109.75)

(A Top Pick May 13/16. Up 30.65%.) The leader in sleep apnea, and primarily manufactures the masks. Recently sold his holdings.

(A Top Pick Feb 11/16. Up 24%. Up 24%.) Sleep apnea is such an unaware market. 26% of the population have it, and the penetration is less than 15%. Last year, there was a lot of built-up demand for the masks that they create, because the new line was being rolled out. They’ve rolled out the new masks, and there has been more demand than had been expected. The dividend is just under 2%. He is continuing to buy this.

(A Top Pick Jan 11/16. Up 33.32%.) This company deals with sleep apnea by providing masks and devices. The opportunity on this is that they are very close to a refresh cycle with their masks, and there is some pent-up demand waiting for the new models to come out.

This deals with sleep apnea by producing the mask and the device that helps deliver the oxygen. 26% of adults suffer from sleep apnea. In developed markets it has only about 10%-15% penetration, and in emerging markets only 5%, so he likes the upside. Dividend yield of 2.09%.

Some of the shareholders are super bright buys. They have a good shareholder base. They had a bit of a failure to launch. They don’t have a long shelf life. You have a more activist board that are shaking the tree. It is going to have prospects. He wants to see something happen with their capital.

Sleep Apnea. It is quite prevalent – 25% of the population have it. 2.12% dividend. It is the leader to provide the devices.

They address sleep apnea. It affects many more people than we think. Many have it and are not aware of it. They are the leader in the space. They build the machine and the custom mask. It is a space that is very much underpenetrated. He sees growth in the share price.